Literature DB >> 2337444

Bile rifaximin concentration after oral administration in patients undergoing cholecystectomy.

S Verardi1, V Verardi.   

Abstract

Rifaximin, a new antibiotic derived from rifamycin SV, was measured in the cholecystic bile of 13 patients submitted to cholecystectomy, after oral administration of 1600 mg of the drug in the 48 hour preceding surgery. Rifaximin concentrations were quantified only in 6 patients and were at least five times lower than those detected with rifampicin, under similar experimental conditions. Results seem to indicate that rifaximin is virtually not absorbed through the intestinal mucosa after oral administration.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2337444

Source DB:  PubMed          Journal:  Farmaco        ISSN: 0014-827X


  5 in total

Review 1.  Management of covert hepatic encephalopathy.

Authors:  Abhijeet Waghray; Nisheet Waghray; Kevin Mullen
Journal:  J Clin Exp Hepatol       Date:  2014-04-01

2.  In vitro activity and fecal concentration of rifaximin after oral administration.

Authors:  Z D Jiang; S Ke; E Palazzini; L Riopel; H Dupont
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

Review 3.  BDDCS, the Rule of 5 and drugability.

Authors:  Leslie Z Benet; Chelsea M Hosey; Oleg Ursu; Tudor I Oprea
Journal:  Adv Drug Deliv Rev       Date:  2016-05-13       Impact factor: 15.470

Review 4.  Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.

Authors:  J C Gillis; R N Brogden
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

5.  Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers.

Authors:  Corrado Blandizzi; Giuseppe Claudio Viscomi; Carmelo Scarpignato
Journal:  Drug Des Devel Ther       Date:  2014-12-16       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.